María Pilar
Garrido López
Profesor/a Asociado/a en CC. de la Salud
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (2)
2023
-
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 181-193
2017
-
Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial
JAMA - Journal of the American Medical Association, Vol. 317, Núm. 18, pp. 1844-1853